Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced unaudited interim and annual consolidated financial results for the fourth quarter and year ended December 31, 2007. The unaudited financial results are subject to further review and potential adjustment as described under the section "Financial Information".

"Throughout 2007, we continued to build our business with the launch of new products, the receipt of regulatory approvals, and the establishment of new partnerships. We expect our new product pipeline and our portfolio of innovative currently marketed products to provide growth and opportunity in 2008 and beyond," said Dr. William Hunter, President and CEO of Angiotech.

"With our expanded sales and marketing team in place and many of our reorganization activities completed, we believe that we are well positioned to achieve our targets for sales growth and gross margin improvements in the coming year," said Tom Bailey, Chief Financial Officer of Angiotech. "We are confident that during 2008 we will begin to realize returns on the various investments we have made in our business over the last two years."

Fourth Quarter Financial Highlights

- Total revenue, as adjusted for non-recurring items, was

$70.7 million. Total revenue under generally accepted accounting

principles (GAAP) was $71.4 million.

- Net product sales, as adjusted, were $43.5 million, and were derived

primarily from sales of our various single use specialty medical

devices as well as from sales of medical device components to third

parties. Net produ
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Colo. , July 31, 2014 ... awardee today with $25,000 to fund a translational ... inception in 2011, the gift was presented at ... Annual Meeting in Colorado Springs, ... specialize in neurointerventional approaches to neurovascular conditions, SNIS ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® ... bearings are uniquely suited to prevent loss of lubrication ... the high temperatures . , Recently, a manufacturer ... engineers at Graphite Metallizing to overcome problems with movement ... operation, pans containing blocks of powder mixture are loaded ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... -- Smith & Nephew (LSE:SN, NYSE: SNN ... its entry into the forefoot market with the ... Comprised of three separate repair options, the HAT-TRICK ... and reconstruction, a metatarsal osteotomy guide, and a ... also known as hammer toe correction. ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4
... SAN DIEGO, Oct. 27 BioAtom Inc. (private) announced,today ... Investor Conference on,Tuesday, October 28, 2008 at 2:30 PM ... in San Diego, California., Myron Karasik, M.B.A., C.M.C., ... of BioAtom Inc. of Costa Mesa, CA, dedicated,to development ...
... YORK, Oct. 24 The day of true ... study confirms the efficacy of a,revolutionary egg selection ... a viable and reliable fertility preservation option., ... ReproCure, a,vanguard genetics products company, this process increases ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... therapy and oncology, today announced that it received ... Zentaris that during the 30,consecutive business days prior ... the,Company,s common shares had closed below the US$1.00 ...
Cached Biology Technology:BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2Breakthrough Technology Takes Egg Freezing from Myth to Dependable Reality 2Breakthrough Technology Takes Egg Freezing from Myth to Dependable Reality 3Breakthrough Technology Takes Egg Freezing from Myth to Dependable Reality 4AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3
(Date:7/31/2014)... An international team of scientists from Spain, France, ... rove beetle that is the oldest definitive member ... found in amber. The discovery and description were ... phase-contrast X-ray synchrotron imaging technique, which allows the ... amber. The new species is described in the ...
(Date:7/31/2014)... Edmond Becquerel first discovered the photovoltaic effect in 1839, ... power of sunlight for its own purposes. In a ... of the FASEB Journal , scientists ... power of sunlight by focusing on a naturally occurring ... evolution. This conservationor persistence over time and across speciessuggests ...
(Date:7/31/2014)... people are familiar with Hibiscus flowers- they are ... they are commonly planted in the landscape. Some, ... are endangered species. , Only a relatively few ... of an equally beautiful and intriguing related group ... "brother of Hibiscus". , Brother of Hibiscus species ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Brother of Hibiscus is found alive and well on Maui 2
... researchers is examining a new vaccine method that may ... and his team of researchers is hoping to find ... smaller doses and require only one trip to the ... prepared from killed bacteria. The vaccinated person,s immune system ...
... of the future plan to confront the greatest scientific, ... inhabitants? This is the question being addressed at the ... Status and Perspective held by the Deutsche Forschungsgemeinschaft (DFG, ... Promotion of Science (JSPS), taking place in Hamburg this ...
... in French . A research ... Universitys Department of Microbiology and Immunology has discovered that ... the bodys autoimmune reactions may lose their effectiveness and ... type 1 diabetes. The study conducted on non-obese ...
Cached Biology News:Iowa State researchers look for smaller, cheaper, 1-dose vaccines 2Japanese and German researchers meet to discuss climate change 2Japanese and German researchers meet to discuss climate change 3Type 1 diabetes triggered by 'lazy' regulatory T-cells: McGill researchers 2